



Published in final edited form as:

Chem Commun (Camb). 2017 July 20; 53(59): 8280–8283. doi:10.1039/c7cc04090c.

Highly efficient chemoenzymatic synthesis and facile purification of α -Gal pentasaccharyl ceramide Gal α 3nLc $_4$ β Cer

Abhishek Santra^a, Yanhong Li^a, Hai Yu^a, Teri J. Slack^a, Peng George Wang^b, and Xi Chen^a

^aDepartment of Chemistry, University of California, One shields Avenue, Davis, CA, 95616, USA.
Tel: +1 530 754-6037; Fax: +1 530 752-8995


^bDepartment of Chemistry and Center of Diagnostics & Therapeutics, Georgia State University, Atlanta, GA 30303, USA

Abstract

A highly efficient chemoenzymatic method for synthesizing glycosphingolipids using α -Gal pentasaccharyl ceramide as an example is reported here. Enzymatic extension of chemically synthesized lactosyl sphingosine using efficient sequential one-pot multienzyme (OPME) reactions allowed glycosylation be carried out in aqueous solution. Facile C18 cartridge-based quick (<30 minutes) purification protocols were established using minimal amounts of green solvents (CH₃CN and H₂O). Simple acylation in the last step led to the formation of the target glycosyl ceramide in 4 steps with an overall yield of 57%.

Graphical abstract

α -Gal pentasaccharyl ceramide was synthesized using sequential one-pot multienzyme (OPME) systems with facile purification by C18 cartridge followed by acylation.



Glycosphingolipids (GSLs) are glycoconjugates consisting of an oligosaccharide linked to a ceramide, a lipid consisting of a sphingoid base (sphingosine in mammalian

Correspondence to: Xi Chen.

[†]Electronic Supplementary Information (ESI) available: Experimental details for chemical and enzymatic synthesis, NMR and HRMS data, and NMR spectra. See DOI: 10.1039/x0xx00000x

glycosphingolipids). In ceramide, the amino group of the sphingoid base was coupled to a fatty acid via an amide bond.¹ GSLs are ubiquitous components of mammalian cell membranes and are well known for their important roles in human health and diseases.²⁻⁶ De novo synthesis of glycosphingolipids in nature involves the formation of ceramide⁷ at the cytoplasmic face of the endoplasmic reticulum (ER), transfer of the ceramide to the cytoplasmic face of the Golgi, formation of glucosylceramide and translocation to the luminal face of the Golgi, and subsequent extension of the oligosaccharide chain by glycosyltransferases for the formation of more complex glycosphingolipids in the Golgi, followed by delivery to cell surface.² All complex glycosphingolipids share a common lactosyl ceramide (Lac β Cer) core.⁸⁻¹⁰ Lac β Cer has a low solubility in water and is a poor acceptor for *in vitro* enzymatic reactions using glycosyltransferases in aqueous solutions.^{9, 10}

GSLs used in functional studies and clinical applications have been commonly purified from mammalian cells, blood, and/or tissues.¹¹⁻¹³ The inherited heterogeneity, the presence of other compounds with similar properties, and potential contamination by infectious agents¹¹ make large scale purification of desired glycosphingolipids challenging, especially for low abundant compounds.

Complex GSLs are also challenging synthetic targets despite advances in the development of modern chemical, enzymatic, and chemoenzymatic methods. A general strategy for synthesizing GSLs has been using multistep chemical synthesis¹⁴⁻¹⁷ of a trichloroacetimidate glycosyl donor^{16, 18-21} for coupling with an azido derivative of the protected glycosphingosine followed by reduction of the azido group, coupling with an acyl chain, and deprotection. Unavoidably, the chemical synthetic approaches involve multiple tedious protection and deprotection processes which lead to extended preparation time and low overall yields. Alternatively, glycans synthesized enzymatically and chemoenzymatically have been protected and activated to generate glycosyl donors, such as trichloroacetimidate²¹ and more recently perbenzoylated glycosyl *N*-phenyltrifluoroacetimidate, for chemical glycosylation with a selectively benzoyl protected azido-sphingosine as the glycosylation acceptor. Another chemoenzymatic strategy is an endoglycoceramidase glycosynthase strategy using an oligosaccharyl fluoride as the donor substrate and a sphingoid base or its derivative as the acceptor substrate.^{11, 22} Both chemoenzymatic strategies require pre-assembly of non-protected oligosaccharides or oligosaccharyl fluorides in aqueous solution which involve time-consuming non-trivial purification of non-protected glycans after each glycosylation step. The products that can be obtained by glycosynthase-catalyzed direct glycosylation strategy are also limited by the substrate specificities of the enzyme mutants used towards both the glycan and the lipid components.

We propose an alternative chemoenzymatic strategy for synthesizing GSLs. As shown in Scheme 1, we envision that complex glycosphingosines can be readily obtained by sequential glycosyltransferase-dependent one-pot multienzyme (OPME) systems to extend the glycan chain in lactosyl sphingosine (Lac β Sph), a glycolipid that is readily soluble in aqueous solutions. The sphingosine (lipid) component in the glycosyl sphingosine products can be used as a hydrophobic tag, allowing facile purification of the product by C18

cartridge with simple green solvents such as acetonitrile and water. Acylation of the glycosyl sphingosine product with a fatty acid will form desired glycosphingolipids. The method allows the enzyme-catalyzed glycosylation reactions to occur in aqueous solutions and facile purifications by solid-phase extraction.²³ An additional advantage is that intermediates for long chain complex glycosphingosines can be acylated to form other naturally occurring glycosphingolipids.

For a proof-of-concept experiment, α -Gal pentasaccharyl ceramide (Gal α 3Gal β 4GlcNAc β 3Gal β 4Glc β Cer) or α 1–3-galactosyl-lacto-*N*-neotetraosyl β -ceramide Gal α 3nLc $_4$ β Cer (**1**) (Scheme 1) was chosen as a target for synthesis. Gal α 3nLc $_4$ β Cer (**1**) was initially identified from rabbit red blood cells.²⁴ It was later found to be the major non-acid glycosphingolipid in pig kidney²⁵ and the major α -Gal structure in pig aorta.²⁶ Together with other α -Gal epitopes, it binds to naturally existing human anti-Gal antibodies and is a major cause for organ rejection in pig to human xenotransplantation.^{27–29}

For economic and effective chemoenzymatic synthesis of glycosphingolipids using the proposed method, the first step is to identify an efficient chemical method for large-scale synthesis of lactosyl sphingosine (Lac β Sph) from commercially available inexpensive phytosphingosine (**6**) and lactose.

According to several previous reports^{30–32} for the synthesis of glucosyl, galactosyl, or lactosyl sphingosine, the azido-derivative of sphingosine was a better acceptor than other *N*-protected sphingosine derivatives for glycosylation with trichloroacetimidate glycosylation donors. For example, our attempts for glycosylation using *N*-tetrachlorophthaloyl (*N*-TCP) protected acceptor³⁰ and lactosyl trichloroacetimidate led to very low yields. In addition to using the azido protecting group, benzoyl protection of the secondary alcohol in sphingosine was designed to improve the regioselectivity of glycosylation. Therefore, 2-azido-3-*O*-benzoyl sphingosine (**12**) (Scheme 2) was chosen as the glycosylation acceptor for the formation of lactosyl sphingosine. An efficient strategy³³ was chosen to synthesize **12** from inexpensive D-erythro-sphingosine (or phytosphingosine, **6**) by converting its amino group to an azido group by treating with freshly prepared triflic-azide in the presence of catalytic CuSO₄ and triethylamine to form compound **7** in a quantitative yield without chromatographic purification. The primary hydroxyl of **7** was selectively protected by *tert*-butyldiphenylsilyl (TBDPS) group³³ to produce **8** in 98% yield. Conversion of the 3,4-vicinal diol in **8** to its cyclic sulfate (**9**) was achieved in high yield (92%) by using thionyl chloride in the presence of triethylamine followed by oxidation with RuCl₃/NaIO₄. Selectively opening of the cyclic sulfate by tetrabutylammonium iodide and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), dehydrohalogenation to form alkene, followed by acidic hydrolysis to remove the allylic *O*-sulfate group were carried out in one pot³³ to furnish compound **10** in 85% yield. Conventional benzylation of compound **10** produced **11** in 95% yield. Removal of the *O*-sialyl ether of **11** was carried out using HF·pyridine to produce the glycosylation acceptor **12** (2.3 grams) in 97% yield. The total yield for the chemical synthesis of the compound **12** from phytosphingosine **6** was 61% in six steps.

Glycosylation of **12** with per-*O*-benzoyl lactosyl trichloroacetimidate (**13**)³⁴ in the presence of BF₃·OEt₂ in CH₂Cl₂ at -18 °C produced per-*O*-benzoyl lactoside (**14**)³⁵ in 90% yield

(Scheme 3). After removal of all benzoyl protecting groups by the Zemplén condition, several methods were tested to reduce the azido group while keep the alkene group intact. Methods using PPh_3 ,³⁶ PMe_3 ,³⁷ or Lindlar catalyst³⁸ led to poor yields (30–50%). The combination of 1,3-propanedithiol and triethylamine³⁹ were found to be the most efficient for selective reduction of the azido group to produce Lac β Sph (5) in an excellent yield (94%). The total yield for the glycosylation was 85% in three steps and the total yield for chemical synthesis of Lac β Sph (5) was 52% in nine steps.

Lactosyl sphingosine (Lac β Sph, 5) was readily soluble in aqueous solution for up to 30 mM, allowing it be used efficiently as a starting glycosyltransferase acceptor for enzymatic extension using one-pot multienzyme (OPME) reactions^{23, 40–45} for the synthesis of more complex structurally diverse glycosphingosines. The sphingosine (lipid) component of the acceptor and the product can be used as an anchor to allow facile purification of the glycosphingosines by reverse phase column chromatography such as simple C18 cartridge-based purification.

For the synthesis of the target α -Gal pentasaccharyl ceramide Gal α 3nLc $_4\beta$ Cer (1), α -Gal pentasaccharyl sphingosine Gal α 3nLc $_4\beta$ Sph (2) was synthesized by enzymatic extension from Lac β Sph (5) using a sequential OPME strategy involving three OPME reactions (Scheme 4). Formation of trisaccharyl sphingosine Lc $_3\beta$ Sph (GlcNAc β 3Gal β 4Glc β Sph, 4) from Lac β Sph (5) was achieved by a one-pot four-enzyme N-acetylglucosamine (GlcNAc) activation and transfer system containing *Bifidobacterium longum* (strain ATCC55813) N-acetylhexosamine-1-kinase (BLNahK),⁴⁶ *Pasteurella multocida* N-acetylglucosamine uridylyltransferase (PmGlmU),⁴⁷ *Pasteurella multocida* inorganic pyrophosphatase (PmPpA),⁴⁸ and *Neisseria meningitidis* β 1–3-N-acetylglucosaminyltransferase (NmLgtA)⁴⁹ in Tris-HCl buffer (100 mM, pH 8.0) at 37 °C for 52 hours. The BLNahK, PmGlmU, and PmPpA allowed in situ formation of uridine 5'-diphosphate-N-acetylglucosamine (UDP-GlcNAc), the sugar nucleotide donor substrate, efficiently and directly from monosaccharide GlcNAc for NmLgtA-catalyze formation of Lc $_3\beta$ Sph (4). Upon the completion of the enzymatic reaction as monitored by thin-layer chromatography (TLC) and high-resolution mass spectrometry (HRMS), the reaction mixture was diluted with the same volume of ethanol. The solution was incubated at 4 °C for 30 minutes and centrifuged to remove precipitates. The supernatant was concentrated and the residue was dissolved in 2–3 mL of water at 40–45 °C. The solution was directly loaded to a pre-conditioned C18 cartridge. The cartridge was then washed with 0.01% TFA in water (10 mL) using a syringe. The unreacted sugar, adenosine 5'-triphosphate (ATP), uridine 5'-triphosphate (UTP), adenosine 5'-diphosphate (ADP), uridine 5'-diphosphate (UDP), UDP-sugar, and salts were completely removed in this step. The product Lc $_3\beta$ Sph (4) was eluted by 37% acetonitrile in 0.01% TFA/H $_2$ O and unreacted starting material was eluted with 50% acetonitrile in 0.01% TFA/H $_2$ O. The purification process took less than 30 min in contrast to several hours using standard silica gel chromatography. A yield of 83% was achieved after purification.

The obtained Lc $_3\beta$ Sph (4) was used for synthesizing nLc $_4\beta$ Sph (3) using an improved OPME galactose (Gal) activation and transfer system⁵⁰ containing *Streptococcus pneumoniae* TIGR4 galactokinase (SpGalK),⁵¹ *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP),⁵⁰ PmPpA, and *Neisseria meningitidis* β 1–4-

galactosyltransferase (NmLgtB)^{48, 49} in Tris-HCl buffer (100 mM, pH 8.0) at 37 °C for 30 hours. The SpGalK, BLUSP, and PmPpA allowed in situ formation of uridine 5'-diphosphate-galactose (UDP-Gal), the donor substrate of NmLgtB, from monosaccharide galactose (Gal) for the formation of LNNtβSph (**3**). A similar C18-cartridge purification procedure was carried out as described above for Lc₃βSph (**4**) except that 35% acetonitrile in 0.01% TFA/H₂O was used as an eluant to purify nLc₄βSph (**3**). The acceptor was completely consumed. After purification, a yield of 92% was obtained.

The last OPME reaction was carried out to convert the obtained nLc₄βSph (**3**) to Galα3nLc₄βSph (**2**) using a galactose activation and transfer system containing SpGalK, BLUSP, PmPpA, and a recombinant bovine α1-3-galactosyltransferase (Ba1-3GalT)^{23, 52} in Tris-HCl buffer (100 mM, pH 7.5) at 37 °C for 48 hours. The donor substrate UDP-Gal was generated from galactose in situ as described in the previous step for stereo-selective production of the desired Galα3nLc₄βSph (**2**). The enzymatic introduction of the terminal α1-3-linked galactoside by the Ba1-3GalT was especially advantageous as the 1,2-cis-glycosylation is more challenging to achieve by chemical glycosylation strategies. The product (88% yield) was purified by C18-cartridge with elution using 32% acetonitrile in 0.1% TFA in H₂O and the unreacted acceptor was eluted with 35% or a higher concentration (50%) of acetonitrile in 0.1% TFA/H₂O.

It is worth to mention that 1.5 equivalents of nucleoside triphosphates (ATP and UTP) were used in each OPME reaction to optimize the glycosylation yields. With decreased costs of these compounds, in situ recycling of ATP and UTP was not necessary for preparative or gram-scale reactions.

The target Galα3nLc₄βCer (**1**) was readily obtained in 85% yield by *N*-acylation of Galα3nLc₄βSph (**2**) with palmitic acid in the presence of EDC·HCl, HOBt and Et₃N.¹⁸ Overall, the chemoenzymatic route provided the target Galα3nLc₄βCer (**1**) with an overall 30% yield in 13 steps. Although Galα3nLc₄βCer (**1**) had low solubility in methanol as noticed previously,¹⁵ its solubility in CD₃OD was sufficient to allow detailed nuclear magnetic resonance characterization of the product.

In conclusion, using α-Gal pentasaccharyl ceramide synthesis as an example, we have demonstrated that efficient sequential one-pot multienzyme (OPME) chemoenzymatic systems can be combined with facile C18-purification processes for high-yield production of glycosphingosines and glycosylceramides. The strategy can be extended to the synthesis of other complex glycosphingolipids. The method and the established protocols will allow non-specialists for synthesizing, purifying, and study desired glycosphingolipids of interest in their own labs with a general research lab setting.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


Acknowledgments

This work was supported by NIH grant U01GM120419 and NSF grant CHE-1300449. Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538. Y.L., H.Y., and X.C. are co-founders of Glycohub, Inc., a company focused on the development of carbohydrate-based reagents, diagnostics, and therapeutics. Glycohub, Inc. played no role in the design, execution, interpretation, or publication of this study.


References

- Lowther J, Naismith JH, Dunn TM, Campopiano DJ. *Biochem Soc Trans.* 2012; 40:547–554. [PubMed: 22616865]
- Schulze H, Sandhoff K. *Cold Spring Harb Perspect Biol.* 2011; 3 pii: a004804.
- Zhang X, Kiechle FL. *Ann Clin Lab Sci.* 2004; 34:3–13. [PubMed: 15038664]
- Cummings RD. *Mol Biosyst.* 2009; 5:1087–1104. [PubMed: 19756298]
- Schnaar RL. *J Mol Biol.* 2016; 428:3325–3336. [PubMed: 27261254]
- Mather AR, Siskind LJ. *Adv Exp Med Biol.* 2011; 721:121–138. [PubMed: 21910086]
- Merrill AH Jr. *J Biol Chem.* 2002; 277:25843–25846. [PubMed: 12011104]
- Rearick JI, Sadler JE, Paulson JC, Hill RL. *J Biol Chem.* 1979; 254:4444–4451. [PubMed: 438198]
- Basu SC. *Glycobiology.* 1991; 1:469–475. [PubMed: 1822228]
- Guilbert B, Flitsch SL. *J Chem Soc Perkin Trans 1.* 1994:1181–1186.
- Vaughan MD, Johnson K, DeFrees S, Tang X, Warren RA, Withers SG. *J Am Chem Soc.* 2006; 128:6300–6301. [PubMed: 16683778]
- Masson EA, Sibille E, Martine L, Chaux-Picquet F, Bretillon L, Berdeaux O. *J Lipid Res.* 2015; 56:1821–1835. [PubMed: 26142958]
- Svennerholm L, Fredman P. *Biochim Biophys Acta.* 1980; 617:97–109. [PubMed: 7353026]
- Wang Y, Huang X, Zhang LH, Ye XS. *Org Lett.* 2004; 6:4415–4417. [PubMed: 15548039]
- Gege C, Kinzy W, Schmidt RR. *Carbohydr Res.* 2000; 328:459–466. [PubMed: 11093701]
- Bommer R, Schmidt RR. *Liebigs Annalen der Chemie.* 1989; 1989:1107–1111.
- Chen W, Xia C, Wang J, Thapa P, Li Y, Talukdar A, Nadas J, Zhang W, Zhou D, Wang PG. *J Org Chem.* 2007; 72:9914–9923. [PubMed: 18020363]
- Schutte OM, Ries A, Orth A, Patalag LJ, Romer W, Steinem C, Werz DB. *Chem Sci.* 2014; 5:3104–3114.
- Nakashima S, Ando H, Saito R, Tamai H, Ishida H, Kiso M. *Chem Asian J.* 2012; 7:1041–1051. [PubMed: 22334413]
- Fujikawa K, Nakashima S, Konishi M, Fuse T, Komura N, Ando T, Ando H, Yuki N, Ishida H, Kiso M. *Chem Eur J.* 2011; 17:5641–5651. [PubMed: 21469228]
- Yao Q, Song J, Xia C, Zhang W, Wang PG. *Org Lett.* 2006; 8:911–914. [PubMed: 16494472]
- Rich JR, Cunningham AM, Gilbert M, Withers SG. *Chem Commun.* 2011; 47:10806–10808.
- Hwang J, Yu H, Malekan H, Sugiarto G, Li Y, Qu J, Nguyen V, Wu D, Chen X. *Chem Commun.* 2014; 50:3159–3162.
- Eto T, Ichikawa Y, Nishimura K, Ando S, Yamakawa T. *J Biochem.* 1968; 64:205–213. [PubMed: 4304380]
- Samuelsson BE, Rydberg L, Breimer ME, Backer A, Gustavsson M, Holgersson J, Karlsson E, Uytterwaal AC, Cairns T, Welsh K. *Immunol Rev.* 1994; 141:151–168. [PubMed: 7532617]
- Hallberg EC, Stokan V, Cairns TD, Breimer ME, Samuelsson BE. *Xenotransplantation.* 1998; 5:246–256. [PubMed: 9915252]
- Fryer JP, Leventhal JR, Matas AJ. *Transpl Immunol.* 1995; 3:21–31. [PubMed: 7551975]
- Sandrin MS, McKenzie IF. *Curr Opin Immunol.* 1999; 11:527–531. [PubMed: 10508710]
- Macher BA, Galili U. *Biochim Biophys Acta.* 2008; 1780:75–88. [PubMed: 18047841]
- Di Benedetto R, Zanetti L, Varese M, Rajabi M, Di Brisco R, Panza L. *Org Lett.* 2014; 16:952–955. [PubMed: 24428384]
- Rai AN, Basu A. *J Org Chem.* 2005; 70:8228–8230. [PubMed: 16277356]


32. Zhang Y, Toyokuni T, Ruan F, Hakomori Si. *Glycoconj J*. 2001; 18:557–563. [PubMed: 12151717]
33. Kim S, Lee S, Lee T, Ko H, Kim D. *J Org Chem*. 2006; 71:8661–8664. [PubMed: 17064054]
34. Liu Y, Ding N, Xiao H, Li Y. *J Carbohydr Chem*. 2006; 25:471–489.
35. Zimmermann P, Sommer R, Bär T, Schmidt RR. *J Carbohydr Chem*. 1988; 7:435–452.
36. Long DE, Karmakar P, Wall KA, Suchek SJ. *Bioorg Med Chem*. 2014; 22:5279–5289. [PubMed: 25172148]
37. Nyffeler PT, Liang CH, Koeller KM, Wong CH. *J Am Chem Soc*. 2002; 124:10773–10778. [PubMed: 12207533]
38. Reddy PG, Pratap TV, Kumar GDK, Mohanty Subhendu K, Baskaran S. *Eur J Org Chem*. 2002; 2002:3740–3743.
39. Bayley H, Standring DN, Knowles JR. *Tetrahedron Lett*. 1978; 19:3633–3634.
40. Yu H, Cheng J, Ding L, Khedri Z, Chen Y, Chin S, Lau K, Tiwari VK, Chen X. *J Am Chem Soc*. 2009; 131:18467–18477. [PubMed: 19947630]
41. Huang S, Yu H, Chen X. *Sci China Chem*. 2011; 54:117–128. [PubMed: 21686057]
42. Chen Y, Li Y, Yu H, Sugiarto G, Thon V, Hwang J, Ding L, Hie L, Chen X. *Angew Chem Int Ed Engl*. 2013; 52:11852–11856. [PubMed: 24038939]
43. Yu H, Lau K, Thon V, Autran CA, Jantscher-Krenn E, Xue M, Li Y, Sugiarto G, Qu J, Mu S, Ding L, Bode L, Chen X. *Angew Chem Int Ed Engl*. 2014; 53:6687–6691. [PubMed: 24848971]
44. Meng X, Yao W, Cheng J, Zhang X, Jin L, Yu H, Chen X, Wang F, Cao H. *J Am Chem Soc*. 2014; 136:5205–5208. [PubMed: 24649890]
45. Santra A, Yu H, Tasnima N, Muthana MM, Li Y, Zeng J, Kenyon NJ, Louie AY, Chen X. *Chem Sci*. 2016; 7:2827–2831. [PubMed: 28138383]
46. Li Y, Yu H, Chen Y, Lau K, Cai L, Cao H, Tiwari VK, Qu J, Thon V, Wang PG, Chen X. *Molecules*. 2011; 16:6396–6407. [PubMed: 21799473]
47. Chen Y, Thon V, Li Y, Yu H, Ding L, Lau K, Qu J, Hie L, Chen X. *Chem Commun*. 2011; 47:10815–10817.
48. Lau K, Thon V, Yu H, Ding L, Chen Y, Muthana MM, Wong D, Huang R, Chen X. *Chem Commun*. 2010; 46:6066–6068.
49. Li Y, Xue M, Sheng X, Yu H, Zeng J, Thon V, Chen Y, Muthana MM, Wang PG, Chen X. *Bioorg Med Chem*. 2016; 24:1696–1705. [PubMed: 26968649]
50. Chen X, Fang J, Zhang J, Liu Z, Shao J, Kowal P, Andreana P, Wang PG. *J Am Chem Soc*. 2001; 123:2081–2082. [PubMed: 11456841]
51. Chen M, Chen LL, Zou Y, Xue M, Liang M, Jin L, Guan WY, Shen J, Wang W, Wang L, Liu J, Wang PG. *Carbohydr Res*. 2011; 346:2421–2425. [PubMed: 21903203]
52. Fang J, Li J, Chen X, Zhang Y, Wang J, Guo Z, Zhang W, Yu L, Brew K, Wang PG. *J Am Chem Soc*. 1998; 120:6635–6638.

**Scheme 1.**


An efficient chemoenzymatic strategy for synthesizing complex glycosphingolipids by enzymatic extension of lactosyl sphingosine (LacβSph, 3) using sequential one-pot multienzyme (OPME) reactions with C18-cartridge purification after each glycosylation reaction followed by a simple acylation process. The structures of target α-Gal pentasaccharyl sphingosine Galα3nLc₄βSph (2) and α-Gal pentasaccharyl ceramide Galα3nLc₄βCer (1) are also shown.

**Scheme 2.**

Synthesis of sphingosine acceptor **12**. *Reagents and conditions:* (a) TfN_3 , CuSO_4 , Et_3N , MeOH , CH_2Cl_2 , H_2O , r.t., 6h, > 90%; (b) TBDPSCl , Et_3N , DMAP , CH_2Cl_2 , r.t., 8h, 98%; (c) SO_2Cl_2 , Et_3N , CH_2Cl_2 , 0°C , 0.5–1 h; (d) $\text{RuCl}_3 \cdot 3\text{H}_2\text{O}$, NaIO_4 , CCl_4 : CH_3CN : H_2O (1:1:1), r.t., 2 h; 89% in two steps (e) (i) Bu_4NI , DBU , Toluene, reflux, 4 h; (ii) $\text{H}_2\text{SO}_4/\text{H}_2\text{O}/\text{THF}$, r.t., 45 min; 85% in two steps (f) BzCl , DMAP , Et_3N , CH_2Cl_2 , 0°C to r.t., 12 h, 95%; (g) HF Pyridine, THF , 0°C to r.t., 12 h, 97%.

**Scheme 3.**

Synthesis of lactosyl sphingosine (LacβSph, 5). *Reagents and conditions:* (a) $\text{BF}_3 \cdot \text{OEt}_2$, CH_2Cl_2 , -18°C , 3 h, 90%; (b) NaOMe, MeOH, r.t., 14 h; (c) 1,3-propanedithiol, Et_3N , pyridine-water (1:1 v/v), 50°C , 36 h, 94% in two steps.



Scheme 4.

High-yield synthesis of α -Gal pentasaccharyl ceramide Gal α 3nLc $_4\beta$ Cer (**1**) by enzymatic extension of lactosyl sphingosine (Lac β Sph, **5**) using sequential one-pot multienzyme (OPME) reactions with C18-cartridge purification for the formation of α -Gal pentasaccharyl sphingosine Gal α 3nLc $_4\beta$ Sph (**2**) followed by a simple acylation reaction.